Cabaletta Bio (CABA) Capital Leases (2024 - 2026)
Cabaletta Bio (CABA) posted quarterly Capital Leases of $2.9 million for Q4 2025, down 11.17% year-over-year from $3.2 million in Q4 2024, and down 36.84% quarter-over-quarter from $4.6 million in Q3 2025.
Cabaletta Bio (CABA) Capital Leases (2024 - 2026) Analysis & Trends
Cabaletta Bio's Capital Leases history runs 2 years deep, the most recent figure standing at $2.9 million for Q4 2025.
- In Q4 2025, Capital Leases fell 11.17% year-over-year to $2.9 million; the TTM figure through Dec 2025 stood at $2.9 million (down 11.17% YoY), while the FY2025 annual figure was $2.9 million, down 11.17% from the prior year.
- Capital Leases for Q4 2025 stood at $2.9 million, down from $4.6 million in the prior quarter.
- The five-year high for Capital Leases was $8.1 million in Q1 2025, with the low at $2.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cabaletta Bio | 466.25 Mn | 466.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.74 Mn |
| Dec 31, 2025 | 2.88 Mn |
| Sep 30, 2025 | 4.56 Mn |
| Jun 30, 2025 | 3.90 Mn |
| Mar 31, 2025 | 8.11 Mn |
| Dec 31, 2024 | 3.24 Mn |